胰腺癌预后相关免疫组织化学标志物研究进展  

Research progress of immunohistochemical markers related with pancreatic cancer prognosis

作　　者：祝鹏[1] 刘慧颖[2] 胡志前[1] 王伟军[1] 

机构地区：[1]第二军医大学附属长征医院普外科,上海200003 [2]第二军医大学附属东方肝胆外科医院分子肿瘤实验室

出　　处：《国际肿瘤学杂志》2014年第10期767-770,共4页Journal of International Oncology

摘　　要：虽然胰腺癌诊断与治疗的方法和技术已取得长足的进步,但是胰腺癌患者的预后依然得不到很大提升,这与胰腺癌细胞的恶性程度不无关系.研究表明,正常胰腺细胞在恶化成胰腺癌细胞的过程中,共需要具备6种能力,这些能力与胰腺癌细胞的恶性程度密切相关.多种与胰腺癌预后相关的免疫组织化学标志物参与了胰腺细胞获得这6种能力的过程.Pancreatic cancer is a malignant with very poor prognosis. Although methods and technolo- gies of diagnosis and treatment in connection with pancreatic cancer have made great progresses, the prognoses of patients with pancreatic cancer still have not a significant upgrade, which are closely related with the degree of malignancy of pancreatic cancer ceils. Earlier studies have shown that normal pancreatic cells need to have a total of six capabilities, which are intimate connection with the degree of malignancy of pancreatic cancer cells, during the process of deterioration. A variety of immunohistochemical markers that correlate with prognosis of pancreatic cancer involve in the process of pancreatic cells obtaining these six capabilities.

关 键 词：胰腺肿瘤 预后 肿瘤标记 生物学 

分 类 号：R735.9[医药卫生—肿瘤]